Cargando…

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells

Tumor immunotherapy based on the use of chimeric antigen receptor modified T cells (CAR T cells) is a promising approach for the treatment of refractory hematological malignancies. However, a robust response mediated by CAR T cells is observed only in a minority of patients and the expansion and per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otáhal, Pavel, Průková, Dana, Král, Vlastimil, Fabry, Milan, Vočková, Petra, Latečková, Lucie, Trněný, Marek, Klener, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839314/ https://www.ncbi.nlm.nih.gov/pubmed/27141398 http://dx.doi.org/10.1080/2162402X.2015.1115940

Ejemplares similares

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents
por: Klanova, Magdalena, et al.
Publicado: (2014)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
por: Polgárová, Kamila, et al.
Publicado: (2022)

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic
por: Obr, Ales, et al.
Publicado: (2022)

Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
por: Jakša, Radek, et al.
Publicado: (2022)

Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report
por: Klanova, Magdalena, et al.
Publicado: (2012)

Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience
por: Polgárová, Kamila, et al.
Publicado: (2022)

Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells
por: Lorkova, Lucie, et al.
Publicado: (2015)

Antitumor effect of lenalidomide in malignant glioma cell lines
por: Hanashima, Yuya, et al.
Publicado: (2020)

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy
por: Malarikova, Diana, et al.
Publicado: (2020)

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma
por: Ogunnaike, Edikan A., et al.
Publicado: (2021)

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
por: Klener, Pavel
Publicado: (2019)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2015)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2016)

BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor
por: Tang, Jiaxing, et al.
Publicado: (2021)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
por: Alvarez‐Fernández, Carmen, et al.
Publicado: (2021)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
Publicado: (2022)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Galunisertib enhances chimeric antigen receptor-modified T cell function
por: Wang, Zhixiong, et al.
Publicado: (2020)

Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
por: Kranz, Emiko, et al.
Publicado: (2022)

Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
por: Sommermeyer, Daniel, et al.
Publicado: (2015)

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2022)

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma
por: Tomida, Akimasa, et al.
Publicado: (2021)

M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors
por: Huo, Yi, et al.
Publicado: (2023)

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2020)

Drug Resistance in Non-Hodgkin Lymphomas
por: Klener, Pavel, et al.
Publicado: (2020)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
por: Zhang, Erhao, et al.
Publicado: (2018)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
por: Zou, Yixin, et al.
Publicado: (2018)

Research advances in chimeric antigen receptor-modified T-cell therapy (Review)
por: Luo, Yuxi, et al.
Publicado: (2021)

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021)

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma
por: Ping, Nana, et al.
Publicado: (2022)

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma
por: Havranek, Ondrej, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vb02mbs248p54mofintuqcblc9